Literature DB >> 26093379

Genetic Variants of VEGF (rs201963 and rs3025039) and KDR (rs7667298, rs2305948, and rs1870377) Are Associated with Glioma Risk in a Han Chinese Population: a Case-Control Study.

Jiannan Zhang1, Jian Yang2, Yuqing Chen3, Qin Mao2, Shanquan Li2, Wenhao Xiong2, Yingying Lin1, Jie Chen4, Jianwei Ge5.   

Abstract

A glioma is the most common type of brain tumor that accounts for nearly 80 % of brain cancers. Vascular endothelial growth factor (VEGF) and its receptor, the kinase insert domain receptor (KDR), are involved in the angiogenesis of cancers. In this study, we investigate whether the polymorphisms of VEGF and KDR are associated with a glioma risk. Blood samples were collected from 477 glioma patients and 477 healthy controls. Five tag-single nucleotide polymorphisms (SNPs) of KDR were obtained from the HapMap database, and eight tag-SNPs of VEGF were selected based on previous studies. After extraction of genomic DNAs by a Qiagen DNA blood kit, the SNPs of VEGF and KDR were genotyped with a Sequenom MassArray iPLEX platform and further analyzed with matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometry. The odds ratios and their 95% confidence interval (95% CI) were used to assess the association between VEGF, KDR polymorphisms, and glioma risks with the aid of SPSS 13.0 software. The haplotype analysis demonstrated that two SNPs of VEGF [rs3025039 (C>T), rs2010963 (G>C)] could elevate the susceptibility to a glioma in the homozygous model [odds ratio (OR) = 3.13 (95% confidence interval (CI) 1.30-7.49, P = 0.007) and OR = 1.58 (95% CI 1.07-2.34, P = 0.022), respectively], dominant model [OR = 1.38 (95% CI 1.04-1.84, P = 0.025) and OR = 1.32 (95% CI 1.01-1.72, P = 0.043), respectively], and allelic model [OR = 1.43 (95% CI 1.11-1.84, P = 0.005) and OR = 1.24 (95% CI 1.04-1.50, P = 0.019), respectively]. Furthermore, three SNPs of KDR [rs7667298 (A>G), rs2305948 (C>T), rs1870377 (T>A)] were also assumed to be associated with an increased risk of a glioma in the homozygous [OR = 1.93 (95% CI 1.30-2.86, P = 0.001), OR = 2.56 (95% CI 1.28-5.11, P = 0.006), and OR = 1.52 (95% CI 1.00-2.31, P = 0.049), respectively], dominant [OR = 1.52 (95% CI 1.16-1.98, P = 0.002), OR = 1.41 (95% CI 1.05-1.87, P = 0.020), and OR = 1.48 (95% CI 1.13-1.93, P = 0.004), respectively], and allele models [OR = 1.39 (95% CI 1.15-1.67, P = 0.001), OR = 1.47 (95% CI 1.14-1.89, P = 0.002), and OR = 1.27 (95% CI 1.05-1.52, P = 0.013), respectively]. The genetic polymorphisms of VEGF [rs3025039 (C>T), rs2010963 (G>C)] and KDR [rs7667298 (A>G), rs2305948 (C>T), rs1870377 (T>A)] increased glioma susceptibility in a Chinese population, suggesting the possibility of VEGF and KDR as genetic markers for glioma. Additional functional and association studies with different ethnic groups included are needed to further confirm our results.

Entities:  

Keywords:  Genetic markers; Glioma; Han Chinese population; Kinase insert domain receptor; Single nucleotide polymorphism; Vascular endothelial growth factor

Mesh:

Substances:

Year:  2015        PMID: 26093379     DOI: 10.1007/s12035-015-9240-0

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  38 in total

1.  Association of age-related macular degeneration with polymorphisms in vascular endothelial growth factor and its receptor.

Authors:  Alessandro Galan; Alberto Ferlin; Luigi Caretti; Genny Buson; Giovanni Sato; Anna Chiara Frigo; Carlo Foresta
Journal:  Ophthalmology       Date:  2010-05-14       Impact factor: 12.079

2.  Vascular endothelial growth factor expression in stage I non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis.

Authors:  H Han; J F Silverman; T S Santucci; R S Macherey; T A d'Amato; M Y Tung; R J Weyant; R J Landreneau
Journal:  Ann Surg Oncol       Date:  2001 Jan-Feb       Impact factor: 5.344

Review 3.  Clinical implications of genetic variations in the VEGF system in relation to colorectal cancer.

Authors:  Torben Frøstrup Hansen; Anders Jakobsen
Journal:  Pharmacogenomics       Date:  2011-12       Impact factor: 2.533

4.  Genetic variation in VEGF family genes and breast cancer risk: a report from the Shanghai Breast Cancer Genetics Study.

Authors:  Alicia Beeghly-Fadiel; Xiao-Ou Shu; Wei Lu; Jirong Long; Qiuyin Cai; Yong-Bing Xiang; Ying Zheng; Zhongming Zhao; Kai Gu; Yu-Tang Gao; Wei Zheng
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-11-30       Impact factor: 4.254

5.  Chromosome 7p11.2 (EGFR) variation influences glioma risk.

Authors:  Marc Sanson; Fay J Hosking; Sanjay Shete; Diana Zelenika; Sara E Dobbins; Yussanne Ma; Victor Enciso-Mora; Ahmed Idbaih; Jean-Yves Delattre; Khe Hoang-Xuan; Yannick Marie; Blandine Boisselier; Catherine Carpentier; Xiao-Wei Wang; Anna Luisa Di Stefano; Marianne Labussière; Konstantinos Gousias; Johannes Schramm; Anne Boland; Doris Lechner; Ivo Gut; Georgina Armstrong; Yanhong Liu; Robert Yu; Ching Lau; Maria Chiara Di Bernardo; Lindsay B Robertson; Kenneth Muir; Sarah Hepworth; Anthony Swerdlow; Minouk J Schoemaker; H-Erich Wichmann; Martina Müller; Stefan Schreiber; Andre Franke; Susanne Moebus; Lewin Eisele; Asta Försti; Kari Hemminki; Mark Lathrop; Melissa Bondy; Richard S Houlston; Matthias Simon
Journal:  Hum Mol Genet       Date:  2011-04-29       Impact factor: 6.150

6.  Autocrine and paracrine functions of vascular endothelial growth factor (VEGF) in renal tubular epithelial cells.

Authors:  Guillermo Villegas; Bäerbel Lange-Sperandio; Alda Tufro
Journal:  Kidney Int       Date:  2005-02       Impact factor: 10.612

7.  Potentially functional polymorphisms of the vascular endothelial growth factor gene and risk of gastric cancer.

Authors:  Qiao Ke; Jie Liang; Li-Na Wang; Zhi-Bin Hu; Guang-Fu Jin; Yan Zhou; Jian-Ming Wang; Yong-Fei Tan; Zhao-Lai Hua; Yao-Chu Xu; Jing Shen; Hong-Bing Shen
Journal:  Mol Carcinog       Date:  2008-08       Impact factor: 4.784

8.  Autocrine regulation of glioblastoma cell cycle progression, viability and radioresistance through the VEGF-VEGFR2 (KDR) interplay.

Authors:  Petra Knizetova; Jiri Ehrmann; Alice Hlobilkova; Iveta Vancova; Ondrej Kalita; Zdenek Kolar; Jiri Bartek
Journal:  Cell Cycle       Date:  2008-08-12       Impact factor: 4.534

9.  Polymorphisms in the vascular endothelial growth factor gene and breast cancer in the Cancer Prevention Study II cohort.

Authors:  Eric J Jacobs; Heather Spencer Feigelson; Elizabeth B Bain; Kerri A Brady; Carmen Rodriguez; Victoria L Stevens; Alpa V Patel; Michael J Thun; Eugenia E Calle
Journal:  Breast Cancer Res       Date:  2006-04-13       Impact factor: 6.466

10.  Elevated expressions of survivin and VEGF protein are strong independent predictors of survival in advanced nasopharyngeal carcinoma.

Authors:  Yu-Hong Li; Chun-Fang Hu; Qiong Shao; Ma-Yan Huang; Jing-Hui Hou; Dan Xie; Yi-Xin Zeng; Jian-Yong Shao
Journal:  J Transl Med       Date:  2008-01-03       Impact factor: 5.531

View more
  12 in total

Review 1.  Genetic polymorphisms associated with adverse reactions of molecular-targeted therapies in renal cell carcinoma.

Authors:  Kazuhiro Yamamoto; Ikuko Yano
Journal:  Med Oncol       Date:  2018-01-04       Impact factor: 3.064

2.  A microRNA binding site polymorphism in the 3' UTR region of VEGF-A gene modifies colorectal cancer risk based on ethnicity: a meta-analysis.

Authors:  Sai Sushmitha Kontham; Charles Emmanuel Jebaraj Walter; Zioni Sangeetha Shankaran; Arvind Ramanathan; Nirmala Karuppasamy; Thanka Johnson
Journal:  J Egypt Natl Canc Inst       Date:  2022-04-25

3.  Clinical Relevance of VEGFA (rs3025039) +936 C>T Polymorphism in Primary Myelofibrosis: Susceptibility, Clinical Co-Variates, and Outcomes.

Authors:  Laura Villani; Adriana Carolei; Vittorio Rosti; Margherita Massa; Rita Campanelli; Paolo Catarsi; Carlotta Abbà; Robert Peter Gale; Giovanni Barosi
Journal:  Genes (Basel)       Date:  2021-08-20       Impact factor: 4.096

4.  The KDR (VEGFR-2) Genetic Polymorphism Q472H and c-KIT Polymorphism M541L Are Associated With More Aggressive Behaviour in Astrocytic Gliomas.

Authors:  Niyaz Zaman; Serena Santhana Dass; Persephone DU Parcq; Suzanne Macmahon; Lewis Gallagher; Lisa Thompson; Jamshid S Khorashad; Clara LimbÄck-Stanic
Journal:  Cancer Genomics Proteomics       Date:  2020 Nov-Dec       Impact factor: 4.069

5.  MiR-135a and MRP1 play pivotal roles in the selective lethality of phenethyl isothiocyanate to malignant glioma cells.

Authors:  Taolan Zhang; Yingying Shao; Tang-Yuan Chu; Hsuan-Shun Huang; Yu-Ligh Liou; Qing Li; Honghao Zhou
Journal:  Am J Cancer Res       Date:  2016-05-01       Impact factor: 6.166

6.  KRAS and VEGF gene 3'-UTR single nucleotide polymorphisms predicted susceptibility in colorectal cancer.

Authors:  Minnan Yang; Xiuli Xiao; Xiaorui Xing; Xin Li; Tian Xia; Hanan Long
Journal:  PLoS One       Date:  2017-03-22       Impact factor: 3.240

7.  Impact of VEGFA polymorphisms on glioma risk in Chinese.

Authors:  Peng Zhao; Anjing Chen; Qichao Qi; Wenjing Zhou; Zichao Feng; Jiwei Wang; Ning Yang; Xingang Li; Jian Wang; Qibing Huang; Bin Huang
Journal:  Oncotarget       Date:  2017-07-19

8.  Clinical Relevance of +936 C>T VEGFA and c.233C>T bFGF Polymorphisms in Chronic Lymphocytic Leukemia.

Authors:  Sandra Ballester; Begoña Pineda; Patricia Rodrigues; Eduardo Tormo; María José Terol; Pilar Eroles
Journal:  Genes (Basel)       Date:  2020-06-23       Impact factor: 4.096

9.  NRP-1 and KDR polymorphisms are associated with survival time in patients with advanced gastric cancer.

Authors:  Yue-Jian Zhuo; Yu Shi; Tao Wu
Journal:  Oncol Lett       Date:  2019-09-10       Impact factor: 2.967

10.  The Impact of Kinase Insert Domain (KDR) Gene Polymorphism rs2305948 on Clopidogrel Resistance in Iraqi Patients Undergoing Elective Percutaneous Coronary Intervention (PCI).

Authors:  Ali A Ahmed; Khalid I Amber; Najah R Hadi
Journal:  Acta Inform Med       Date:  2020-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.